These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 20527889

  • 1. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M, Higgins JD, Kwong E, Templeton AC.
    J Med Chem; 2010 Aug 26; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract] [Full Text] [Related]

  • 2. Applications of high-throughput ADME in drug discovery.
    Kassel DB.
    Curr Opin Chem Biol; 2004 Jun 26; 8(3):339-45. PubMed ID: 15183334
    [Abstract] [Full Text] [Related]

  • 3. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J, Skolnik S.
    Chem Biodivers; 2009 Nov 26; 6(11):1887-99. PubMed ID: 19937823
    [Abstract] [Full Text] [Related]

  • 4. Developing early formulations: practice and perspective.
    Li P, Zhao L.
    Int J Pharm; 2007 Aug 16; 341(1-2):1-19. PubMed ID: 17658228
    [Abstract] [Full Text] [Related]

  • 5. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D, Yu LX, Hussain MA, Wall DA, Smith RL, Amidon GL.
    Curr Opin Drug Discov Devel; 2004 Jan 16; 7(1):75-85. PubMed ID: 14982151
    [Abstract] [Full Text] [Related]

  • 6. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA.
    Chem Res Toxicol; 2011 Sep 19; 24(9):1420-56. PubMed ID: 21790149
    [Abstract] [Full Text] [Related]

  • 7. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE, Yuen N, Al-Ansari M, Bailey J, Fram D, Green DV, Pickett S, Vitulli G, Luengo JI, Almenoff JS.
    Drug Discov Today; 2011 Aug 19; 16(15-16):646-53. PubMed ID: 21601652
    [Abstract] [Full Text] [Related]

  • 8. Nanosuspensions in drug delivery.
    Rabinow BE.
    Nat Rev Drug Discov; 2004 Sep 19; 3(9):785-96. PubMed ID: 15340388
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H.
    Chem Biodivers; 2009 Nov 19; 6(11):1760-6. PubMed ID: 19937820
    [Abstract] [Full Text] [Related]

  • 11. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):275-300. PubMed ID: 14962582
    [Abstract] [Full Text] [Related]

  • 12. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE, Lopez-Anaya A.
    Curr Opin Drug Discov Devel; 2004 Jan 23; 7(1):126-36. PubMed ID: 14982156
    [Abstract] [Full Text] [Related]

  • 13. Mitigating permeability-mediated risks in drug discovery.
    Wang J, Skolnik S.
    Expert Opin Drug Metab Toxicol; 2010 Feb 23; 6(2):171-87. PubMed ID: 20064074
    [Abstract] [Full Text] [Related]

  • 14. In vitro methods to assess drug precipitation.
    Dai WG.
    Int J Pharm; 2010 Jun 30; 393(1-2):1-16. PubMed ID: 20347943
    [Abstract] [Full Text] [Related]

  • 15. Toward a new age of cellular pharmacokinetics in drug discovery.
    Zhou F, Zhang J, Li P, Niu F, Wu X, Wang G, Roberts MS.
    Drug Metab Rev; 2011 Aug 30; 43(3):335-45. PubMed ID: 21395404
    [Abstract] [Full Text] [Related]

  • 16. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
    Nassar AE, Kamel AM, Clarimont C.
    Drug Discov Today; 2004 Dec 01; 9(23):1020-8. PubMed ID: 15574318
    [Abstract] [Full Text] [Related]

  • 17. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S, Hamon J, Bojanic D, Urban L.
    Drug Discov Today; 2005 Nov 01; 10(21):1421-33. PubMed ID: 16243262
    [Abstract] [Full Text] [Related]

  • 18. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB, Pikal MJ, Shanker RM, Bogner RH.
    Pharm Dev Technol; 2011 Jun 01; 16(3):187-200. PubMed ID: 20429826
    [Abstract] [Full Text] [Related]

  • 19. Gastrointestinal absorption II. Formulation factors affecting drug bioavailability.
    Blanchard J.
    Am J Pharm Sci Support Public Health; 1978 Jun 01; 150(5):132-51. PubMed ID: 364993
    [No Abstract] [Full Text] [Related]

  • 20. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.
    Cole S, Bagal S, El-Kattan A, Fenner K, Hay T, Kempshall S, Lunn G, Varma M, Stupple P, Speed W.
    Xenobiotica; 2012 Jan 01; 42(1):11-27. PubMed ID: 21970687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.